Cargando…

Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity

BACKGROUND: Triple-negative breast cancer (TNBC) remains recalcitrant to most targeted therapy approaches. However, recent clinical studies suggest that inducing tumor damage can render TNBC responsive to immunotherapy. We therefore tested a strategy for immune sensitization of murine TNBC (4T1 tumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheybani, Natasha D, Witter, Alexandra R, Thim, Eric A, Yagita, Hideo, Bullock, Timothy N J, Price, Richard J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443308/ https://www.ncbi.nlm.nih.gov/pubmed/32819975 http://dx.doi.org/10.1136/jitc-2020-001008

Ejemplares similares

Solid Tumor Treatment via Augmentation of Bioactive C6 Ceramide Levels with Thermally Ablative Focused Ultrasound
por: Thim, E. Andrew, et al.
Publicado: (2023)

Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy
por: Qu, Shibin, et al.
Publicado: (2020)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
por: Chen, Xiaofeng, et al.
Publicado: (2020)

Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
por: Feng, Kaichao, et al.
Publicado: (2020)

Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response
por: Qi, Xiaoqiang, et al.
Publicado: (2020)

Focused Ultrasound Hyperthermia Augments Release of Glioma-derived Extracellular Vesicles with Differential Immunomodulatory Capacity
por: Sheybani, Natasha D., et al.
Publicado: (2020)

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
por: Ding, Liya, et al.
Publicado: (2023)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
por: Abe, Shinya, et al.
Publicado: (2022)

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
por: Yoshida, Tatsuya, et al.
Publicado: (2020)

Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
por: Lampert, Erika J, et al.
Publicado: (2020)

Focused Ultrasound Immunotherapy for Central Nervous System Pathologies: Challenges and Opportunities
por: Curley, Colleen T., et al.
Publicado: (2017)

Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist
por: Meneveau, Max O, et al.
Publicado: (2021)

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
por: Vavolizza, Rick D, et al.
Publicado: (2022)

Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial
por: Hochberg, Jessica, et al.
Publicado: (2022)

Perspectives on Recent Progress in Focused Ultrasound Immunotherapy
por: Sheybani, Natasha D., et al.
Publicado: (2019)

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
por: Patel, Sapna P, et al.
Publicado: (2021)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)
por: Slingluff, Jr., Craig L, et al.
Publicado: (2021)

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma
por: Engelhard, Victor H, et al.
Publicado: (2020)

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
por: Seto, Takashi, et al.
Publicado: (2022)

Immune checkpoint inhibitor-associated celiac disease
por: Badran, Yousef R, et al.
Publicado: (2020)

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
por: Leighl, Natasha B, et al.
Publicado: (2021)

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
por: Friedman, Claire F, et al.
Publicado: (2020)

Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial
por: Dietz, Michelle V, et al.
Publicado: (2023)

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
por: Zubiri, Leyre, et al.
Publicado: (2021)

Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients
por: Gérard, Alexandre, et al.
Publicado: (2021)

Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
por: Ataca Atilla, Pinar, et al.
Publicado: (2020)

Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies
por: Rouhani, Sherin Juliet, et al.
Publicado: (2022)

Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
por: Carpenter, Elizabeth Lee, et al.
Publicado: (2023)

Senescent cancer cell vaccines induce cytotoxic T cell responses targeting primary tumors and disseminated tumor cells
por: Liu, Yue, et al.
Publicado: (2023)

CD163(+) cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer
por: Santegoets, Saskia J, et al.
Publicado: (2020)

Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
por: Nebot-Bral, Laetitia, et al.
Publicado: (2022)

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
por: Wislez, Marie, et al.
Publicado: (2022)

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study
por: Ji, Niannian, et al.
Publicado: (2021)

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
por: Tsai, Yo-Ting, et al.
Publicado: (2022)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
por: Barsoumian, Hampartsoum B, et al.
Publicado: (2020)

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
por: Hurkmans, Daan P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_etklti26mn5i9g1ns88ss77rhg